Johnson & Johnson(JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Latest News & Analysis
Johnson & Johnson Q2 2025 Analysis: Pharma Growth, MedTech Innovation & Strategic Resilience
Explore Johnson & Johnson's Q2 2025 earnings beat, pharma segment growth, MedTech advances, and pipeline catalysts amid biosimilar competition and updated guidance.
Johnson & Johnson Q2 2025 Analysis: Pharma Growth, Pipeline Strength & Dividend Stability | Monexa AI
Explore Johnson & Johnson's Q2 2025 pharma growth drivers, pipeline prospects, and dividend sustainability amid market shifts and biosimilar competition.
Johnson & Johnson Latest Corporate Developments and Financial Analysis 2025 | Monexa AI
Explore Johnson & Johnson's latest Q2 2025 financial results, strategic moves, and market positioning with data-driven insights for informed investing.
Johnson & Johnson (JNJ) Q2 2025 Earnings Beat and Guidance Raise Fuel Growth in Innovative Medicine and MedTech
Johnson & Johnson (JNJ) delivers a strong Q2 2025 earnings beat, driven by Oncology, Neuroscience, and MedTech, raising full-year guidance amid biosimilar challenges.
Johnson & Johnson Q2 2025 Analysis: Navigating Patent Headwinds with Pipeline and Diversification
Johnson & Johnson faces a $2B Q2 2025 headwind from Stelara's patent loss, offset by a strong pharma pipeline and MedTech growth, sustaining dividends and resilience.
Johnson & Johnson (JNJ) Latest Financial and Strategic Update - Market Insights
Johnson & Johnson's recent financial results and strategic moves reveal key trends shaping its market position and investor outlook in 2025.
Johnson & Johnson (JNJ) Latest Financial and Strategic Update: Earnings, M&A, and Market Position
Explore Johnson & Johnson's recent financial results, strategic acquisitions, and market positioning with detailed insights into earnings, cash flow, and competitive landscape.
Johnson & Johnson (JNJ) Q2 2025 Update: Navigating Innovative Medicine Growth Amid Stelara LOE and Legal Challenges
Johnson & Johnson's Q2 2025 highlights focus on innovative medicine growth, Stelara patent expiry impacts, MedTech dynamics, and ongoing talc litigation risks.
Johnson & Johnson (JNJ) Latest Financial and Strategic Update: Pipeline Strength Amid MedTech Challenges
Explore Johnson & Johnson's recent financial performance, pipeline innovation, MedTech segment headwinds, and dividend sustainability in this detailed analysis.
Johnson & Johnson (JNJ): Financial Strength Amidst Strategic Evolution
Explore Johnson & Johnson's latest financial performance, strategic shifts in Pharma and MedTech, dividend strength, and the ongoing talc litigation impact.
JNJ Stock: Pharma Innovation Fuels Growth Amidst Litigation Overhang
Johnson & Johnson leverages robust pharmaceutical innovation to drive growth while navigating litigation, reinforcing its Dividend King status.
Johnson & Johnson (JNJ): Navigating Legal Headwinds Amidst Clinical Breakthroughs
JNJ faces legal setbacks from a recent $8M talc verdict, while simultaneously celebrating major oncology breakthroughs and strategic acquisitions driving future growth.
Johnson & Johnson's Oncology Breakthroughs: Market Impact & Strategic Insights
JNJ's latest clinical trial successes in hematologic cancers, including bispecific antibodies and CAR T-cell therapy, signal robust pipeline growth amidst evolving market dynamics.
Johnson & Johnson (JNJ): Financials, Clinical Advances & Market Outlook
Johnson & Johnson's recent clinical breakthroughs in oncology and significant financial shifts redefine its market trajectory.
Johnson & Johnson (JNJ): Pipeline Breakthroughs and Strategic Growth
Johnson & Johnson's latest clinical trials show promising results for Bleximenib in AML and TREMFYA in PsA, reinforcing its strategic growth in oncology and immunology.
Johnson & Johnson (JNJ): 2025 Strategic Moves and Financial Resilience
Johnson & Johnson's latest financial data reveals a robust pipeline, strategic acquisitions, and a significant dividend increase, navigating biosimilar pressures.
Johnson & Johnson (JNJ) Analysis: Pipeline Wins & Financial Health
Deep dive into Johnson & Johnson's 2025, analyzing key clinical trial successes, regulatory milestones, financial performance, and strategic positioning amidst competitive shifts.
Johnson & Johnson's Oncology Breakthroughs Drive Strategic Focus
Explore J&J's latest clinical trial successes in prostate cancer and multiple myeloma, their strategic impact, financial health, and dividend outlook.
Johnson & Johnson: Navigating Legal Headwinds and Pipeline Shifts
Analysis of Johnson & Johnson's Q1 2025 earnings, talc litigation impact, pipeline updates, financial health, and dividend outlook.
Johnson & Johnson's Q1 2025 Operational Strength and Strategic AI Pivot
JNJ reports strong Q1 2025 operational growth, raises dividend, and refines AI strategy despite FY2024 reported earnings impact from special items. Analysis of financials and pipeline.
Johnson & Johnson: Nipocalimab, DARZALEX®, and Economic Outlook
JNJ navigates innovation, economic challenges, and strategic dividend decisions. Nipocalimab's potential in gMG and DARZALEX®'s impact on multiple myeloma are key.
Johnson & Johnson (JNJ): TREMFYA®, Acquisitions, and Market Analysis
Analysis of Johnson & Johnson (JNJ): TREMFYA® efficacy, Intra-Cellular Therapies acquisition, market resilience, and talc litigation impacts on JNJ stock.
Johnson & Johnson (JNJ): Litigation, Acquisitions, and Investor Outlook
Johnson & Johnson (JNJ) navigates talc litigation setbacks and expands into neuropsychiatry with the Intra-Cellular Therapies acquisition. A look at valuation and investor outlook.
Johnson & Johnson (JNJ): Innovation, Market Impact, and Future Outlook
Johnson & Johnson (JNJ) is navigating a dynamic market. Breakthroughs in oncology and neurology, plus U.S. investments, position JNJ for growth.
Johnson & Johnson: $55B Investment, Tremfya Approval, and Dividend King Status
Analysis of Johnson & Johnson's $55B U.S. investment, Tremfya's FDA approval for Crohn's, and its Dividend King status. Growth strategy & market impact insights.
Johnson & Johnson (JNJ): FDA Approval, US Investment & Market Impact
JNJ is making headlines with Tremfya's FDA approval for Crohn's, a $55B U.S. investment, and oncology advancements. A dividend aristocrat offering stability.
Johnson & Johnson (JNJ): Nipocalimab, Lawsuits, and Dividend Outlook
Johnson & Johnson (JNJ) faces a mix of promising drug developments, legal challenges, and dividend sustainability concerns. Nipocalimab's FDA Fast Track contrasts with Stelara biosimilar risks.
Johnson & Johnson (JNJ): Innovation, Legal Challenges & Market
Comprehensive analysis of Johnson & Johnson (JNJ) examining Icotrokinra's clinical trial results, Kenvue spin-off, ChemImage lawsuit, R&D spending, and defensive stock characteristics.
Johnson & Johnson (JNJ) Analysis: Pipeline, Dividends, Volatility
Analysis of Johnson & Johnson's pipeline shifts, Icotrokinra's potential, Aticaprant's setback, and dividend stability amidst market volatility.
Johnson & Johnson (JNJ): Icotrokinra's Promise, Setbacks, and Resilience
JNJ navigates a dynamic healthcare landscape with Icotrokinra's promise, Aticaprant's setback, and strategic acquisitions, influencing market resilience.
Johnson & Johnson (JNJ): MedTech Expansion Offsets R&D Setbacks in 2025
Johnson & Johnson faces mixed outlook in 2025. R&D setbacks offset by MedTech growth. Dividend Aristocrat status provides stability amid market volatility.
Johnson & Johnson (JNJ): Strategic Shifts, Dividends, and Market Outlook
An intraday snapshot on March 5, 2025 detailing JNJ’s leadership transitions, dividend strategy, and innovative product launches.
Johnson & Johnson (JNJ): Navigating Market Trends
Johnson & Johnson (JNJ) navigates biosimilar competition, strategic acquisitions, and market trends, impacting investors. Stay informed with our in-depth analysis.
Johnson & Johnson (JNJ): Navigating Biosimilars, Acquisitions, and Market Trends
Johnson & Johnson (JNJ) navigates biosimilar competition, strategic acquisitions, and legal challenges in a dynamic healthcare market. Analysis and key insights provided.
Johnson & Johnson (JNJ): Navigating Biosimilars, Legal Battles, and Innovation
Johnson & Johnson navigates biosimilar competition, legal battles, and pharmaceutical innovations, impacting its market position and financial health.
Johnson & Johnson: Developments, Market Impact, and Industry Trends
Analysis of Johnson & Johnson's developments, market impact, and industry trends. Explore the baby powder settlement, biosimilar competition, and TREMFYA's potential.
J&J Under Pressure: Stelara Biosimilar Arrives as TREMFYA Shows Promise
Johnson & Johnson navigates biosimilar competition, promising TREMFYA data, and legal challenges amid a dynamic healthcare landscape.
Johnson & Johnson: Key Developments, Market Impact, and Industry Trends
Johnson & Johnson navigates legal battles, innovation, and market shifts. Key developments include baby powder litigation and Varipulse rollout. Stay informed.
Johnson & Johnson: Baby Powder Settlement, Pipeline Updates, and Market Impact
A detailed update on JNJ’s legal battles, pipeline shifts, and market performance as the company navigates key challenges.
Johnson & Johnson’s $10 Billion Baby Powder Battle: Will It Endure?
An in‐depth update on [JNJ](/dashboard/companies/JNJ)’s legal challenges, pipeline developments and strategic initiatives, with actionable insights for investors.